HLS Therapeutics (HLS) Set to Announce Earnings on Thursday

HLS Therapeutics (TSE:HLSGet Free Report) is set to release its earnings data before the market opens on Thursday, November 7th. Analysts expect HLS Therapeutics to post earnings of C($0.19) per share for the quarter.

HLS Therapeutics (TSE:HLSGet Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported C($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The company had revenue of C$19.87 million during the quarter, compared to the consensus estimate of C$19.25 million.

HLS Therapeutics Stock Down 2.0 %

Shares of TSE HLS opened at C$3.40 on Thursday. The stock has a fifty day moving average price of C$3.50 and a 200 day moving average price of C$3.66. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. HLS Therapeutics has a 12-month low of C$3.00 and a 12-month high of C$5.48. The company has a market cap of C$108.09 million, a P/E ratio of -3.37 and a beta of 1.07.

Analysts Set New Price Targets

Separately, Stifel Nicolaus reduced their price target on HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

Read Our Latest Research Report on HLS

HLS Therapeutics Company Profile

(Get Free Report)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.

Recommended Stories

Earnings History for HLS Therapeutics (TSE:HLS)

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.